Anusha Kambala

GW SMHS student - Johns Hopkins Itch Research Fellow

[Dr. Shawn Kwatra @drshawnkwatra]

Great to join the ⁦@awomansjourney⁩ podcast to I talk all about #itch, with new insights into pathogenesis that we have learned directly from studies with our patients and the landscape of novel therapeutics #dermtwitter https://t.co/PMNno1bcwj

[Dr. Shawn Kwatra @drshawnkwatra]

Sharing my lab’s latest study led by @JuneDeng10 & team in @JAMADerm - https://t.co/PRXgxJ2OFE. Most PN patients are itchy in lesions and in “normal appearing” skin. Here we show circulating blood mediators of PN modulated by nemolizumab (anti-IL31RA) therapy #dermtwitter

[Anusha Kambala @AnushaKambala]

🚀 Big News Alert! 📢 Our team just released a game-changing article about the groundbreaking use of ketamine infusions for neuropathic pruritus! 💊 Finally, a ray of hope for those suffering from this debilitating condition. 🌟#itch
https://t.co/YVyyPt9404

[Chirag Vasavda @c_vasavda]

Excited to share our discovery of genetic susceptibility to prurigo nodularis w a measure of polygenic risk! So grateful for the incredible mentorship and collaborative spirit of @drshawnkwatra @EugeneSemenovMD @SashaGusevPosts

https://t.co/bF80PIBdOD @theJIDJournal #dermtwitter

[Dr. Shawn Kwatra @drshawnkwatra]

The biggest need in #itch clinical management is for safe, effective therapeutics for neuropathic pruritus. Here in @jacionline together with Xinzhong Dong @HHMINEWS & @AnushaKambala we reset our paradigm of neuropathic itch https://t.co/TIIyCmp0fY @itchdoctor thx for the invite!

[Hannah Cornman @HannahCornman]

My first publication as a 1st author in Derm 😊 we found 4x higher prevalence of TB in patients with prurigo nodularis and suggest TB testing during initial PN work up could be beneficial for patient management. https://t.co/j0ujAXJxMI
@drshawnkwatra @AnushaKambala @sriyavreddy

[Dr. Shawn Kwatra @drshawnkwatra]

Excited to share our team’s latest work led by @waleedadawi96 on the various presentations of #eczema in @SkinOfColor patients https://t.co/WqhchiSxds. Looking forward to keep advocating for #diversity in new leadership roles @SkinOfColor & @nationaleczema #dermtwitter

[Dr. Shawn Kwatra @drshawnkwatra]

What a huge honor to present at the @AADskin Late Breaker Session to provide the first glimpse of data from the Olympia 2 phase 3 trial of nemolizumab monotherapy in Prurigo Nodularis! There’s a revolution going on in PN, #Prurigo in #Primetime! #AAD23LateBreaker #dermtwitter

[Anusha Kambala @AnushaKambala]

@HannahCornman Thank you so much Hannah!

[Hannah Cornman @HannahCornman]

Amazing first day in NOLA at the #SOCS2023!! Heard about some really incredible research and celebrated @AnushaKambala winning best abstract presentation! ALSO… beignets!

[Dr. Shawn Kwatra @drshawnkwatra]

Join me @ #AAD2023:

Thursday: 3-3:40 pm - https://t.co/blksxDwzhg

Thursday: 7-8:30 pm - https://t.co/zqLm28KykQ

Friday: 7-9 pm - https://t.co/qb3IVLeS7v

Sunday: 4:30 – 5:30 pm​​ U077 - 1st ever dedicated AAD session for PN, Rooms 243-245

Monday: 10:30-10:50 am - S053

[Dr. Shawn Kwatra @drshawnkwatra]

My lab is thrilled to share our latest work led by @JaPately which features the first single-cell RNA sequencing study on prurigo nodularis https://t.co/EmT6heZRtt. We had several findings that change the way I think about the disease #dermtwitter

[Dr. Shawn Kwatra @drshawnkwatra]

Our study on the circulating plasma proteome of prurigo nodularis (PN) patients just dropped https://t.co/wA2g0CTSoK in @JAADjournals. Led by @vparthas, we show dz heterogeneity and endotypes in line w/the variable response to tx we see clinically @HopkinsMedicine #dermtwitter